首页> 外文期刊>Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis >DR negativity is a distinctive feature of M1/M2 AML cases with NPM1 mutation.
【24h】

DR negativity is a distinctive feature of M1/M2 AML cases with NPM1 mutation.

机译:DR阴性是具有NPM1突变的M1 / M2 AML病例的显着特征。

获取原文
获取原文并翻译 | 示例
           

摘要

Our previous observation of a higher incidence of FLT3-ITD in DR(-) M1/M2 AML than in DR(+) M1/M2 led to an investigation of NPM1 mutation in the same samples, since DR(-) AML and AML with NPM1 mutation share such characteristics as normal karyotype, the absence of CD34, and FLT3-ITD. NPM1 mutation was found in 18 of 26 (69.2%) of DR(-) cases, but not in any of 28 DR(+) cases. FLT3-ITD was noted in 66.7% of the cases with NPM1 mutation. These findings point to DR negativity as another phenotypic feature of AML with NPM1 mutation.
机译:我们先前的观察发现DR(-)M1 / M2 AML中FLT3-ITD的发生率高于DR(+)M1 / M2,导致对相同样品中NPM1突变的研究,因为DR(-)AML和AML与NPM1突变具有正常核型,不存在CD34和FLT3-ITD等特征。在26例DR(-)病例中,有18例(69.2%)发现NPM1突变,但在28例DR(+)病例中未发现NPM1突变。 NPM1突变病例中有66.7%注意到FLT3-ITD。这些发现表明,DR阴性是具有NPM1突变的AML的另一个表型特征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号